Bill Alpert

The SEC will need to have just one commissioner present to have a quorum and be able to approve new regulations or bring an enforcement or conduct other actions.

The funds offer double-digit yields for now, but have been cutting their payouts.

Revere Securities, one of the top underwriters of foreign penny-stock IPOs, agrees to an $800,000 fine for failing to flag suspicious activity without admitting or denying the findings.

Connecticut-based Curaleaf is making a hostile takeover bid for Aurora Cannabis in Edmonton, Alberta, each had market caps above $12 billion.

Congress created the Public Company Accounting Oversight Board in 2002 to police accounting firms in the wake of the Enron and WorldCom scandals.

The deal would have raised little money for the growing business. The offering would have gone almost entirely to cover withholding taxes on employee stock options.

Z Squared began trading on Nasdaq in April, part of a plan to get investors out of a private-equity fund.

Grail stock rises after a FDA advisory panel recommends approval of the biotech’s cancer blood test.

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

Hotel REIT Braemar set a Sept. 14 deadline for nominations of any opposing slate.

Novo announced successful results from a Phase 3 study of its injectable GLP1 drug Wegovy in obese children aged six to 12.

Blackstone and Cliffwater have seen redemption requests of about 10% and 16%, respectively, at their private credit funds.

Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.

Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.

The overlapping portion of Business Development Company funds has risen from about 10% of the average portfolio in 2010 to over 55% today.

Cases have fallen sharply in the Trump administration, but enforcement chief David Woodcock says the agency is gearing up for its new approach.

The tariffs cover a slice of imports from Canada that include plywood, liquor, and hockey gear.

The stock jumps after a melanoma treatment has success in a late-stage trial. One analyst says annual sales could hit $3 billion by 2035.

Blue Owl Technology Finance shares trade at a 31% discount to its portfolio valuation due to fears that AI will disrupt its software borrowers.